Cost-effectiveness of a routine varicella vaccination program for US children
- PMID: 8283587
Cost-effectiveness of a routine varicella vaccination program for US children
Abstract
Objective: To evaluate the economic consequences of a routine varicella vaccination program that targets healthy children.
Methods: Decision analysis was used to compare the costs, outcomes, and cost-effectiveness of a routine vaccination program with no intervention. Clinical outcomes were based on a mathematical model of vaccine efficacy that relied on published and unpublished data and on expert opinion. Medical utilization rates and costs were collected from multiple sources, including the Kaiser Permanente Medical Care Program and the California Hospital Discharge Database.
Results: A routine varicella vaccination program for healthy children would prevent 94% of all potential cases of chickenpox, provided the vaccination coverage rate is 97% at school entry. It would cost approximately $162 million annually if one dose of vaccine per child were recommended at a cost of $35 per dose. From the societal perspective, which includes work-loss costs as well as medical costs, the program would save more than $5 for every dollar invested in vaccination. However, from the health care payer's perspective (medical costs only), the program would cost approximately $2 per chickenpox case prevented, or $2500 per life-year saved. The medical cost of disease prevention was sensitive to the vaccination coverage rate and vaccine price but was relatively insensitive to assumptions about vaccine efficacy within plausible ranges. An additional program for catch-up vaccination of 12-year-olds would have high incremental costs if the vaccination coverage rate of children of preschool age were 97%, but would result in net savings at a coverage rate of 50%.
Conclusions: A routine varicella vaccination program for healthy children would result in net savings from the societal perspective, which includes work-loss costs as well as medical costs. Compared with other prevention programs, it would also be relatively cost-effective from the health care payer's perspective.
Comment in
-
Routine childhood varicella vaccination.JAMA. 1994 Jun 22-29;271(24):1906. JAMA. 1994. PMID: 8043126 No abstract available.
-
Routine childhood varicella vaccination.JAMA. 1994 Jun 22-29;271(24):1906. JAMA. 1994. PMID: 8201730 No abstract available.
Similar articles
-
The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule.Soc Sci Med. 1999 Sep;49(6):763-79. doi: 10.1016/s0277-9536(99)00115-x. Soc Sci Med. 1999. PMID: 10459888
-
Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.Southeast Asian J Trop Med Public Health. 2004 Sep;35(3):693-6. Southeast Asian J Trop Med Public Health. 2004. PMID: 15689089
-
Varicella vaccination in Italy : an economic evaluation of different scenarios.Pharmacoeconomics. 2004;22(13):839-55. doi: 10.2165/00019053-200422130-00003. Pharmacoeconomics. 2004. PMID: 15329030
-
Clinical and economic considerations of vaccination against varicella.Pharmacotherapy. 1997 Jan-Feb;17(1):133-9. Pharmacotherapy. 1997. PMID: 9017774 Review.
-
Cost-effectiveness of varicella vaccination programs: an update of the literature.Expert Rev Vaccines. 2008 Aug;7(6):753-82. doi: 10.1586/14760584.7.6.753. Expert Rev Vaccines. 2008. PMID: 18665775 Review.
Cited by
-
Impact of Vaccines; Health, Economic and Social Perspectives.Front Microbiol. 2020 Jul 14;11:1526. doi: 10.3389/fmicb.2020.01526. eCollection 2020. Front Microbiol. 2020. PMID: 32760367 Free PMC article. Review.
-
The role of funding and policies on innovation in cancer drug development.Ecancermedicalscience. 2010;4:164. doi: 10.3332/ecancer.2010.164. Epub 2010 Feb 3. Ecancermedicalscience. 2010. PMID: 22276026 Free PMC article. No abstract available.
-
25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview.Paediatr Drugs. 2001;3(4):285-92. doi: 10.2165/00128072-200103040-00005. Paediatr Drugs. 2001. PMID: 11354700 Review.
-
COVID-19 Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Cost-Benefit Analysis.Int J Environ Res Public Health. 2022 Jun 26;19(13):7848. doi: 10.3390/ijerph19137848. Int J Environ Res Public Health. 2022. PMID: 35805506 Free PMC article.
-
Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data.Hum Exp Toxicol. 2014 Aug;33(8):886-93. doi: 10.1177/0960327113512340. Epub 2013 Nov 25. Hum Exp Toxicol. 2014. PMID: 24275643 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical